The prognosis in patients with advanced non-small cell (non-oat cell) carcinoma of the lung who were treated with cisplatin-containing chemotherapy can be assessed by a prognostic index using clinical and laboratory data.
Patients selected
(1) non small cell carcinomas: adenocarcinoma, squamous cell, large cell undifferentiated
(2) stage: stages III and IV
Parameters:
(1) number of metastatic sites
(2) gender
(3) serum albumin in g/dL
(4) Eastern Cooperative Oncology Group (ECOG) performance status
(5) serum LDH in IU/L
Parameter
Finding
Value
number of metastatic sites
0
0
1
0.4253
>= 2
2 * (0.4253) = 0.8506
sex
female
0
male
0.6116
serum albumin
>= 3.7 g/dL
0
< 3.7 g/dL
0.4936
ECOG performance status
0
0
1
0.4664
2
2 * (0.4664) = 0.9328
3 or 4
excludes patient (see below)
LDH
<= 350 IU/L
0
> 350 IU/L
0.5242
where:
• ECOG 0 (asymptomatic), 1 (symptomatic but ambulatory), 2 (bedridden < half the day), 3 (bedridden >= half the day), and 4 (chronically bedridden, needing assistance in activities of daily living).
• Patients with ECOG performance status of 3 or 4 were excluded since their prognosis was uniformly poor.
prognostic index =
= (value for metastatic sites) + (value for sex) + (value for serum albumin) + (value for performance status) + (value for LDH)
Interpretation
• minimum prognostic index: 0
• maximum prognostic index: 3.4128
Prognostic Index (Group)
Percent with 1 Year Survival
Percent with 2 Year Survival
Median Survival in Months
Response Rate in Percent
< 1.3 (good)
73.1
26.1
16.5
42.3%
1.3 - 2.1999 (intermediate)
36
11
9.4
30.2%
> = 2.2 (poor)
11.6
0
4.6
29.2%
To read more or access our algorithms and calculators, please log in or register.
